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Bordetella pertussis is a Gram-negative bacterium and the causative agent of whooping cough. Despite high vaccination cover-
age, outbreaks are being increasingly reported worldwide. Possible explanations include adaptation of this pathogen, which may
interfere with recognition by the innate immune system. Here, we describe innate immune recognition and responses to differ-
ent B. pertussis clinical isolates. By using HEK-Blue cells transfected with different pattern recognition receptors, we found that
3 out of 19 clinical isolates failed to activate Toll-like receptor 4 (TLR4). These findings were confirmed by using the monocytic
MM6 cell line. Although incubation with high concentrations of these 3 strains resulted in significant activation of the MM6
cells, it was found to occur mainly through interaction with TLR2 and not through TLR4.When using live bacteria, these 3
strains also failed to activate TLR4 on HEK-Blue cells, and activation of MM6 cells or humanmonocyte-derived dendritic cells
was significantly lower than activation induced by the other 16 strains. Mass spectrum analysis of the lipid Amoieties from these
3 strains indicated an altered structure of this molecule. Gene sequence analysis revealed mutations in genes involved in lipid A
synthesis. Findings from this study indicate that B. pertussis isolates that do not activate TLR4 occur naturally and that this phe-
notype may give this bacterium an advantage in tempering the innate immune response and establishing infection. Knowledge
on the strategies used by this pathogen in evading the host immune response is essential for the improvement of current vaccines
or for the development of new ones.
The innate immune system is the first line of defense againstinvading pathogens. In order to recognize these microorgan-
isms, innate immune cells express multiple pathogen recognition
receptors (PRR) consisting of various receptor families, including
the most-studied Toll-like receptors (TLRs) (1). Evasion of this
first recognition can be critical for the pathogen establishing in-
fection. Additionally, the innate immune system is essential for
the induction and regulation of the adaptive response. For exam-
ple, dendritic cells (DCs) can produce interleukin-12p70 (IL-
12p70), which is associated with the differentiation of T helper 1
(Th1) cells or cytotoxic T cells (2, 3) and IL-1, IL-6, and IL-23,
which are required for differentiation and survival of Th17 cells (4,
5). Pathogen adaptation, through changes in the structure or ex-
pression of molecules which interact with the host, might allow
the pathogen to escape the host immune responses.
Pertussis, also referred to as whooping cough, is a human-
specific respiratory disease caused by the Gram-negative bacte-
rium Bordetella pertussis. It has been shown that B. pertussis is able
to activate both TLR2 andTLR4 signaling on innate immune cells,
which is essential for inducing protective immunity against this
bacterium (6–9). A well-defined ligand for TLR4 is lipopolysac-
charide (LPS), which is produced by Gram-negative bacteria. B.
pertussis also produces LPS; however, it lacks the O-chain struc-
ture and is therefore referred to as lipooligosaccharide (LOS) (10).
TLR4 signaling leads to the induction of proinflammatory cyto-
kines or type I interferon (11). TLR2 recognizes a broad range of
ligands, including lipoproteins and peptidoglycans, and induces
the production of proinflammatory cytokines (12). Since 1990,
outbreaks of pertussis in developed countries have been increas-
ingly reported despite high vaccination coverage (13–16). Several
explanations have been proposed for the upsurge of pertussis,
including waning immunity and adaptation of the pathogen due
to selective pressure induced by the vaccine (16–20).
Indeed, variations in the structure or expression of virulence-
associated proteins of B. pertussis have been observed (21). Based
on the allelic variation in the genes of immunodominant pertussis
toxin subunit A (ptxA), pertactin (prn), promoter for Ptx (ptxP),
and fimbriae3 (fim3), seven allele types (I to VII) have been de-
fined (21). In the past decades, circulating strains have shifted
from ptxP1 to ptxP3, the latter of which is associated with in-
creased Ptx production in vitro (22). Furthermore, an increase in
B. pertussis strains lacking Prn has been recently observed in sev-
eral countries (23–27). Whether naturally occurring gene varia-
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tions inB. pertussis strains have an impact in the recognition of the
innate immune system remains unknown.
Here, we aimed to characterize the interaction between differ-
ent B. pertussis clinical isolates and the innate receptors TLR2 and
TLR4, as well as the consequences for DC activation. For this
purpose, we screened a selection of 19 B. pertussis strains repre-
senting multiple B. pertussis allele types, including the laboratory
Tohama I strain and the 18-323 strain commonly used in experi-
mental models to evaluate pertussis vaccines (28), using HEK-
Blue cells expressing humanTLR2 or TLR4. To verify the findings,
we used a monocytic cell line expressing these and other PRR and
a physiologically relevant innate immune cell type, namely, den-
dritic cells. Results indicated that B. pertussis mutant strains that
do not activate TLR4 occur naturally. The lack of TLR4 activation
could be one of the strategies used by this bacterium to evade and
modulate the host immune response and establish infection.
MATERIALS AND METHODS
Ethics statement.This studywas conducted according to the principles of
Good Clinical Practice. All blood donors provided written informed con-
sent for the collection of samples and subsequent analysis, and the blood
samples were processed anonymously.
Reagents. Ultrapure lipopolysaccharide from Escherichia coli K-12
(LPS-EK), ultrapure lipopolysaccharide from Rhodobacter sphaeroides
(LPS-RS), and PAM3CSK4 were all purchased from InvivoGen. Blocking
anti-TLR2 antibodies were obtained from R&D Systems. Granulocyte-
macrophage colony-stimulating factor (GM-CSF) was purchased from
PeproTech, and recombinant human IL-4 was purchased from Sanquin.
Cell lines. Human NF-B/SEAP reporter HEK293 cells (HEK-Blue)
transfected either with humanTLR2 (HEK-Blue-hTLR2) or humanTLR4
(HEK-Blue-hTRL4) in combination with MD-2 and CD14, as well as
untransfected (HEK-Blue-Null1) cells, were purchased from InvivoGen.
All these cell lines contain an NF-B-inducible secreted embryonic alka-
line phosphatase (SEAP) reporter gene. TLR signaling leads to the expres-
sion of SEAP, which can be detected in culture supernatants after adding
the substrate Quanti-Blue (InvivoGen). The cells were grown in complete
Dulbecco’s modified Eagle’s medium (DMEM; Gibco) supplemented
with 10% heat-inactivated fetal calf serum (FCS; Thermo Scientific), 50
U/ml penicillin (Gibco), 50 g/ml streptomycin (Gibco), 1 HEK-Blue
selection (InvivoGen), and 100g/mlNormocin (InvivoGen); we refer to
this medium here as HEK-Blue culture medium. The HEK-Blue-Null1
cell line was cultured in the HEK-Blue culture medium in the presence of
100 g/ml Zeocin (InvivoGen) instead of 1 HEK-Blue selection. The
human monocytic cell line MonoMac6 (MM6; DSMZ) was grown in
Iscove’s modified Dulbecco’s medium (IMDM; Gibco) enriched with
10% heat-inactivated FCS, 50 U/ml penicillin, and 50 g/ml streptomy-
cin; we refer to this medium here as MM6 culture medium. All cell lines
were cultured at 37°C in a 5% saturated CO2 atmosphere.
Bacterial strains, growth conditions, and sequencing. The selected
19 strains represented multiple B. pertussis allele types based upon the
DNA sequence of the PtxP, Ptx, Prn, and fimbriae genes, which have been
shown to change over time (16). The selected strains included laboratory
strains Tohama I derivative (B0213; streptomycin and naladixic acid re-
sistant) and 18-323 (B1121). The clinical isolates represented ptxP1,
ptxP2, ptxP3, and ptxP4 strains and included vaccine antigen-deficient
strains, lacking the expression of one of the vaccine antigens (21). A de-
tailed overview of the selected B. pertussis strains is given in Table 1. The
DNA sequences of alleles for ptxP, ptxA, and prn were determined previ-
ously (21, 29, 30). The sequences of genes involved in LOS synthesis (Ta-
ble 2) were based on the genome sequences of strains B1121/18-323 (31),
B0442, and B1120 (32). The 19 strains were grown at 35°C on Bordet
Gengou (BG) plates containing glycerol and 15% defibrinated sheep blood
(BDBiosciences).After 3daysof culture, photographsusingProtoCOL(Syn-
biosis) were made to determine whether the strains induced hemolysis. The
bacteria were collected in phosphate-buffered saline (PBS), and the optical
density (OD)wasmeasured at 600nm.Bvg (33) andBvg (34) strainswere
used as positive and negative controls, respectively. Heat-inactivated (1 hour
at 56°C) or live bacteria were used in the experiments.
TLR2 and TLR4 signaling in HEK-Blue cell lines. In a 96-well plate,
2.5 104HEK-Blue-hTLR2,HEK-Blue-hTLR4, orHEK-Blue-Null1 cells
were incubated in HEK-Blue culture medium in the absence or presence
of PAM3CSK4 as the TLR2 ligand or LPS-EK as the TLR4 ligand. In
addition, these cells were incubated with heat-inactivated bacteria (OD,
0.25 to 2.6 108; 5-fold dilutions) or live bacteria (OD, 0.01). After 22 h
of incubation at 37°C, supernatants were collected and the Quanti-Blue
substrate was added. After 2 to 4 h of incubation with the substrate, the
OD values, indicating SEAP activity, were measured using an enzyme-
linked immunosorbent assay (ELISA) reader (OD at 649 nm). In order to
determine whether B. pertussis strains can act as TLR4 antagonists, HEK-
Blue-hTLR4 cells were first preincubated at 37°C with the Tohama I,
B0442, B1120, and B1121 strains (ODs, 0.1, 0.01, and 0.001) or LPS-RS
(10, 1, and 0.1 g/ml) for 3 h, after which LPS-EK (0.0002 g/ml) was
added and the cultures were incubated for 22 h. This suboptimal LPS
concentration was chosen from a titration experiment (see Fig. S4A in the
supplementalmaterial) thatwas used to be able to detect either an increase
or decrease of TLR4 activation after incubation of HEK-TLR4 with the B.
pertussis strains and LPS-EK.
MM6 cell stimulation. MM6 cells were seeded in a 96-well plate at
1.5 105 cells per well in MM6 culture medium. In the blocking experi-
ments, the cells were preincubated with MM6 culture medium or MM6
culture medium supplemented with 1 g/ml LPS-RS or 0.5 g/ml anti-
TLR2 antibodies for 3 h at 37°C. Subsequently, cells were held unstimu-
lated or were stimulated with MM6 culture medium supplemented with
LPS-EK, PAM3CSK4, heat-inactivated bacteria (OD, 0.01, 2  103, or
4  104) or live bacteria (OD, 2  103). After 22 h at 37°C, superna-
tants were collected for IL-6 measurements.
LOS-A and LOS-B ELISA. For the LOS-A and LOS-B ELISAs, a flat-
bottom96-well plate (Immulon-2HB;ThermoScientific)was coated for 2
h at 37°C with a 3-fold-dilution in PBS of different B. pertussis strains
(ODs, 0.081 to 0.0003). Strain B0134 was used as a control, since it only
produces LOS-B (35). Subsequently, the plates were washed with water
containing 0.03% Tween 80 (Merck) and incubated for 1 h at 37°C either
with anti-LOS-A (88F8 [36]) or anti-LOS-B (BL-8 [37]) monoclonal an-
TABLE 1 Bordetella pertussis strains
Designation ptxP allele ptxA allele Remark(s)
Yr of
isolation
B0213 (Tohama I) ptxP1 ptxA1 1953
B0572 ptxP1 ptxA2 1952
B0576 ptxP1 ptxA2 1967
B0582 ptxP1 ptxA1 1972
B1920 ptxP1 ptxA1 2000
B3214 ptxP1 ptxA1 2008
B0496 ptxP2 ptxA4 1950
B1193 ptxP2 ptxA4 1950
B0644 ptxP3 ptxA1 1996
B1917 ptxP3 ptxA1 2000
B2584 ptxP3 ptxA1 2003
B3034 ptxP3 ptxA1 2005
B3640 ptxP3 ptxA1 Prna 2010
B3645 ptxP3 ptxA1 Prna 2007
B3585 ptxP3 ptxA1 FHAb 2009
B3582 ptxP3 ptxA1 Prn,a FHAa 2009
B0442 ptxP4 ptxA5 1954
B1120 ptxP4 ptxA5 1993
B1121 (18-323) ptxP4 ptxA5 1947
a The indicated protein is not expressed (natural mutant).
b The indicated protein is expressed at low levels.
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tibodies diluted 1/100 and 1/10 in PBS containing 1% Tween 80, respec-
tively. After washing, the plates were incubated for 1 h at 37°Cwith horse-
radish peroxidase-labeled goat anti-mouse IgG3 antibody (Southern
Biotech) for detection of LOS-A and Goat-anti-Mouse IgG (Southern
Biotech) for detection of LOS-B diluted in PBS supplemented with 0.1%
Tween 80 and 0.5% Protifar (Nutricia). Following the washing steps, the
peroxidase substrate (0.1mg/ml tetramethylbenzidine with 0.012%H2O2
in 0.11M sodiumacetate buffer [pH5.5]) was added, and the reactionwas
stopped with 2MH2SO4 after 10min. TheOD at 450 nmwas determined
with an ELISA reader.
Analysis of lipid A via ESI-MS. The lipid A moieties of LOS were
isolated from whole bacterial cells, as described previously (38). In short,
the bacteria were washed with a chloroform-methanol solution (3:2, vol/
vol), centrifuged (16,000 g for 10 min), and subsequently washed with
a chloroform-methanol-water solution (12:8:1, vol/vol/vol). Then, after
centrifugation (16,000 g for 10min), the pellets were resuspended in an
isobutyric acid–2 M ammonium hydroxide–water solution (10:3:3, vol/
vol/vol) and heated to 100°C for 2 h under magnetic stirring. Subse-
quently, it was cooled in icewater and centrifuged (16,000 g for 10min).
The supernatants were diluted in 3 ml water and freeze-dried. After
freeze-drying, the pellets were washed twice with methanol and centri-
fuged (4,600  g for 20 min). The pellets were extracted using chloro-
form-methanol-water (12:6:1, vol/vol/vol), centrifuged (4,600 g for 20
min), and the lipid A extract in the upper phase was analyzed by electro-
spray ionization mass spectrometry (ESI-MS) with a Finnigan LCQ in-
strument in the negative-ion mode (39).
Monocyte-derivedDCgeneration and stimulation.Peripheral blood
derived from healthy donors was used for the generation of monocyte-
derived DC (MDDC). First, peripheral bloodmononuclear cells (PBMC)
were obtained by gradient centrifugation at 1,000  g for 30 min on
Lymphoprep (Nycomed). Second, using magnetically activated cell sort-
ing in combination with anti-CD14 microbeads (Miltenyi Biotech),
monocytes were isolated from the PBMC fraction. Monocytes were cul-
tured in a 24-well culture plate (0.4  106 cells/well) in IMDM (Gibco)
supplemented with 1% FCS, 100 units penicillin, 100 units streptomycin,
and 2.92mg/ml L-glutamine (DC culture medium) and in the presence of
500 U/ml GM-CSF and 800 U/ml IL-4 for 6 days. On day 6, the immature
MDDCwere kept unstimulated with DC culture medium containing 250
U/ml GM-CSF or stimulated with DC culture medium containing 250
U/ml GM-CSF and 100 ng/ml LPS-EK or live B. pertussis strains (OD, 4
104). After 48 h, supernatants were collected and stored at80°C, and
subsequently the MDDC were stained with phycoerythrin-conjugated
anti-CD40 (clone 5C3; BD Biosciences), allophycocyanin-conjugated an-
ti-CD80 (clone 2D10; BioLegend), fluorescein isothiocyanate-conjugated
anti-CD83 (clone HB15e; BD Biosciences), Pacific Blue-conjugated anti-
CD86 (clone IT2.2; BioLegend), or with the LIVE/DEAD fixable Aqua
dead cell stain kit (Invitrogen) for 30min at 4°C. TheMDDCwerewashed
twice and resuspended in fluorescence-activated cell sorting (FACS) buf-
fer (PBS [pH 7.2], 0.5% bovine serum albumin, 0.5 mM EDTA). Data
were acquired on a FACSCanto II apparatus (BD Biosciences) and ana-
lyzed using FlowJo software (Tree Star).
Cytokine analysis. In supernatants from the MM6 cultures, IL-6 was
measured using an IL-6 ELISA kit (Sanquin) and transforming growth
factor  (TGF-) was measured in MDDC culture supernatants by using
a TGF- ELISA kit (BioLegend). The ELISAs were performed according
to the manufacturer’s instructions. TGF- was measured in samples that
were either untreated or treated with an acidification and neutralization
solution to activate latent TGF-. The concentrations of various other
cytokines (IL-1, IL-6, IL-8, IL-10, IL12p70, IL-23, and tumor necrosis
factor alpha [TNF-]) were determined in supernatants of the MDDC
cultures by using a human ProcartaPlex multiplex kit (eBioscience) ac-
cording to the manufacturer’s protocol. Measurements and data analysis
were performedwithBio-Plex 200, usingBio-PlexManager software (ver-
sion 5.0; Bio-Rad Laboratories). Results were calculated as mean cytokine
levels relative to the cytokine levels induced by the Tohama I strain (set as
100).
Statistical analysis. All statistical analyses were performed using
GraphPad Prism 6.04. Statistical significance was determined by using a
2-way analysis of variance followed by a Bonferroni post hoc test for the
experiments with the HEK-Blue cell lines and by using an unpaired t test
for the experiments with the MM6 cell line and the MDDC. P values of
	0.05 were considered statistically significant.
RESULTS
Human TLR2 and TLR4 activation by different B. pertussis iso-
lates. To establish whether the 19 selected B. pertussis isolates in-
duced human TLR2 and TLR4 signaling, HEK-Blue cells, express-
ing either of these TLRs, were used. Findings indicated that all of
these B. pertussis clinical isolates activated, in a dose-dependent
manner, TLR2, as indicated by increased SEAP activity (Fig. 1A).
When tested on the HEK-Blue-hTLR4 cell line, 16 out of the 19
heat-inactivated strains clearly induced SEAP activity (Fig. 1B).
However, isolates B0442, B1120, and B1121 were not able to in-
duce TLR4 signaling. To exclude an effect from the heat inactiva-
tion step, the TLR2- and TLR4-transfected HEK-Blue cells were
also incubated with live bacteria (OD, 0.01). Comparable results
were found (Fig. 1C and D), namely, that also the live B0442,
B1120, and B1121 isolates failed to activate TLR4, yet the TLR2
activation was comparable to that induced by the other isolates
(Fig. 1C andD). In order to exclude aspecific SEAP activation due
to signaling via TLR3, TLR5, and NOD1, which are expressed at
low levels in untransfected HEK cells (Invivogen), we incubated
these cells with the 19 isolates. No SEAP activity was found, indi-
cating that results using the TLR2- and TLR4-transfected HEK
cells were specific to these TLRs (see Fig. S1 in the supplemental
material).
Activation of the MM6 cell line by different clinical B. per-
tussis isolates. To determine whether the B. pertussis isolates in-
duced a differential effect on TLR4 activation in the presence of
TABLE 2 Differences in sequences of genes involved in LOS synthesis and modifications
Isolate
lpxA
(BP1431)c
lpxB
(BP1432)
lpxC
(BP3072)
lpxD
(BP1429)
lpxH
(BP1905)
lpxL1
(BP3072)
lpxL2
(BP3073) pagL
lgmA
(BP0399) lgmB (BP0398)
lgmC
(BP0397)
lgmD
(BP0396)
B0442 S173
L Na N R354
C N E111
K K292
E N N N N N
B1120 S173
L N N R354
C N E111
K K292
E N N N N N
B1121 S173
Lb N N N N E111
K K292
E N Nb TT deletion
(frameshift/early
stop codon)b
Absentb Absentb
a N, no difference in gene sequence compared to that in strain Tohama I.
b Results are from Shah et al. (31).
c BP numbers indicate locus tags.
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multiple PRR, MM6, a human monocytic cell line that expresses,
among other PRR, functional TLR2, TLR4, TLR5, and TLR7/8
(40, 41), was used. Strains B0442, B1120, and B1121 only induced
MM6 activation when the cells were incubated with the highest
bacterial concentration (OD, 0.01) (Fig. 2A). The other 16 strains
already induced IL-6 production when the MM6 cells were incu-
bated with the lowest bacterial concentration (OD, 4  104).
Importantly, these findings indicated that even in the presence of
FIG 1 Induction of TLR2 and TLR4 signaling by 19B. pertussis isolates onHEK-Blue-hTLR2/hTLR4 cell lines. (A toD)DifferentHEK-Blue cell lines, expressing
hTLR2 or hTLR4, were stimulated with several concentrations of 19 heat-inactivated (HI) or live B. pertussis isolates. (A and B) TLR activation was measured by
SEAP activity after incubation of HEK-Blue-hTLR2 (A) or HEK-Blue-hTLR4 (B) cells with the heat-inactivated B. pertussis strains (OD, 0.05 to 2.6 108). **,
P 	 0.01; ****, P 	 0.0001, for B1121, B1120, and B0442 strains versus the Tohama I strain. (C and D) Comparison of TLR activation after incubation of
HEK-Blue-hTLR2 (C) or HEK-Blue-hTLR4 (D) cells with heat-inactivated or live B. pertussis strains (OD, 0.01). *, P	 0.01 versus live Tohama I strain;, P	
0.01 versus heat-inactivated Tohama I strain. Data shown are mean values of three independent experiments (A and B) or representative results of at least three
independent experiments (C and D).
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multiple PRR, the B0442, B1120, and B1121 isolates were less ef-
ficient in activating MM6 cells than the other 16 clinical isolates.
Effect of blocking TLR2 and TLR4 signaling on MM6 cells
induced by B. pertussis clinical isolates. Since the B0442, B1120,
and B1121 isolates failed to induce TLR4 signaling with the HEK-
Blue-hTLR4 cell line, we were interested in characterizing the role
of TLR4 signaling in MM6 cell activation by the different B. per-
tussis strains. For this purpose, experiments blocking TLR4 on
these cells were performed. Blocking TLR4 signaling by means of
adding LPS-RS, a TLR4 antagonist (42), resulted in a partial
blocking ofMM6 activation bymost of the strains (Fig. 2B). How-
ever, activation of MM6 cells induced by B. pertussis isolates
B0442, B1120, and B1121, which was already lower than with the
other 16 strains, was not affected by the TLR4 antagonist (Fig. 2B).
To determine the effect of TLR2 signaling on MM6 cells by these
strains, this TLR was blocked by using anti-TLR2 antibodies. In
contrast to the effect of blocking TLR4, activation of the MM6
cells by all 19 strains was blocked when the MM6 cells were pre-
incubatedwith the anti-TLR2 antibodies (Fig. 2C).Notably,MM6
cell activation by the B0442, B1120, and B1121 isolates was com-
pletely blocked. These results indicated that MM6 activation by
the B0442, B1120, and B1121 isolates occurs mainly through in-
teraction with TLR2, whereas the other strains induce both TLR4
and TLR2 signaling. To determine whether the contribution of
FIG 2 Role of TLR2/TLR4 signaling in the activation of MM6 cells by 19 B. pertussis isolates. (A)MM6 cells were incubated with medium or heat-inactivated B.
pertussis isolates (OD, 0.01, 2 103, or 4 104) for 22 h, after which IL-6 production wasmeasured as amarker for cell activation. (B and C) IL-6 production
byMM6 cells stimulated with heat-inactivated B. pertussis (OD, 0.01) after 3 h of preincubation with or without 1g/ml the TLR4 antagonist LPS-RS (B) or with
or without 0.5 g/ml anti-TLR2 antibodies (C). Data shown are representative results of three independent experiments and are reported as the mean IL-6
concentration (in pg/ml) the standard deviation. Background IL-6 production of MM6 cells incubated with medium was 4.02 1.67 pg/ml.
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TLR2 and TLR4 signaling in the activation of MM6 cells by heat-
inactivated bacteria is similar to that of live bacteria, theMM6cells
were incubated with live Tohama I, B0442, B1120, and B1121
bacteria (OD, 2 103). Incubation ofMM6cells with live B0442,
B1120, and B1121 isolates resulted in lower IL-6 production than
in cells incubated with the Tohama I strain (see Fig. S2 in the
supplemental material). Furthermore, while MM6 activation in-
duced by the Tohama I strain could be partially blocked by both
the TLR2 and TLR4 blockers (see Fig. S2), IL-6 production in-
duced by the B0442, B1120, and B1121 isolates was not influenced
when cells were preincubated with the TLR4 blocker, yet it was
completely blocked when cells were preincubated with the anti-
TLR2 antibodies (see Fig. S2). Together, these results indicate that
MM6 cell activation induced either by live or heat-inactivated
B0442, B1120, and B1121 isolates mainly occurs via TLR2 signal-
ing, while for the other strains it occurs via both TLR4 and TLR2
signaling.
LOS characterization. Since the lipid A component of the LOS
molecule is essential for TLR4 signaling (43), we investigated
whether changes in the structure of this molecule could explain
the findings. For this, the structures of the lipid A molecules from
Tohama I, B0442, B1120, and B1121 B. pertussis isolates were de-
termined using mass spectrometry. Interestingly, strain B1121,
also referred to as 18-323, has been previously described to have an
altered LOS structure (44). Results from the mass spectrometry
analysis indicated a peak corresponding with the penta-acyl lipid
A containing a glucosamine (GlcN) substituent (m/z 1,719.1),
which could be identified in the lipid A spectrum of the Tohama I
strain (Fig. 3A). However, the spectra of B0442, B1120, and B1121
lacked this peak, indicating that the lipid As of these strains do not
contain GlcN substituents (Fig. 3B, C, and D). Furthermore, the
spectra of these three isolates showed that the peak of the penta-
acyl lipid A with free phosphate groups was shifted from m/z
1,558.1 toward m/z 1,502.1 and 1,530.1. These findings are in
agreement with the results described by Marr et al., showing that
the two peaks atm/z 1,502.1 and 1,530.1 result from a substitution
of a C14-OH with either a C10-OH or a C12-OH, respectively (44).
These results indicate that the LOS structures for the B0442,
B1120, and B1121 isolates are comparable and that they differ
from the LOS structure of the Tohama I strain. The altered struc-
ture of the lipid A molecules of these three strains can explain the
lack of TLR4 signaling observed. To exclude that the effect seen on
TLR4 signaling is caused by decreased expression of LOS inB0442,
B1120, and B1121, the amounts of type A and B LOS (37) were
determined using an ELISA. Findings showed no significant dif-
ferences in the expression of LOS among the isolates (see Fig. S3 in
the supplemental material), indicating that the diminished TLR4
signaling by these three isolates is not due to decreased expression
of the LOS molecules. Interestingly, preincubation of HEK-Blue-
hTLR4 cells with Tohama I, which optimally activate HEK-TLR4,
did not interfere with TLR4 signaling induced by LPS-EK (see Fig.
S4C in the supplemental material). In contrast, preincubation
with LPS-RS, B0442, B1120, or B1121 inhibited LPS-EK-induced
TLR4 signaling (see Fig. S4B andD to F). These results suggest that
the LOS molecules of isolates B0442, B1120, and B1121, but not
that of B0213, act as TLR4 antagonists.
Gene sequences of LOS-related genes in tested clinical iso-
lates. To determine whether the structural changes found in the
LOS of the B0442, B1120, and B1121 isolates correspond to alter-
ations in the genes involved in LOS synthesis (45), the sequences
FIG 3 Lipid A structures of Tohama I, B0442, B1120, and B1121 B. pertussis
strains. (A to D) Structural analyses of the lipid A moieties of the B. pertussis
isolates Tohama I (A), B0442 (B), B1120 (C), and B1121 (D)was performed by
usingmass spectometry. Peaks atm/z 1,719.1 represent penta-acyl lipid Awith
a GlcNmodification at either phosphate group. Peaks atm/z 1,558.1 represent
penta-acyl lipid A without GlcN modification and with a C14-OH acyl chain,
and the peaks at m/z 1,502.1 and 1,530.1 represent penta-acyl lipid A without
GlcN modification and with a C10-OH and C12-OH acyl chain, respectively.
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of these genes were analyzed and compared to the gene sequence
of the Tohama I strain (Table 2). Shah et al. described for the
B1121/18-323 strain a substitution of a leucine for a serine at
amino acid 173 (S173
L) in the LpxAprotein (31). This is the first
enzyme of the LPS biosynthesis pathway, and it catalyzes acy-
lation of the C-3 position of the UDP N-acetylglucosamine
backbone, forming UDP-3-O-acyl N-acetylglucosamine (46).
Results showed that this same amino acid substitution was ob-
served for the other clinical isolates that showed no TLR4 signal-
ing, namely, B0442 and B1120 (Table 2). Furthermore, the B0442
and B1120 isolates had a mutation in the lpxD gene, and all three
isolates had a mutation in the lpxL1 and lpxL2 genes. These genes
also encode acyltransferases, which can influence the length of the
acyl chains. However, the alteration of the LpxA enzyme is most
likely the cause of the presence of a C10-OH or C12-OH instead of
C14-OH acyl chain on the C-3= position of the diglucosamine
backbone, as proposed by Shah et al. Nomutations were found in
the lpxB, lpxC, lpxH, and pagL genes. Shah et al. also reported a TT
deletion mutation at bp 981 of lgmB (locus tag BP0398) in the
B1121/18-323 strain, which resulted in a lack of GlcN modifica-
tion of the phosphate groups. Interestingly, in the B0442 and
B1120 isolates, this deletion mutation was not found. Therefore,
anothermutationmust be involved in this process. The sequences
of the genes lgmA (locus tag BP0399), lgmC (locus tag BP0397),
and lgmD (locus tag BP0396) were therefore also analyzed for
mutations. However, no mutations in these genes or in the pro-
moter region were observed in these two isolates, suggesting that
another mechanism accounts for the lack of GlcN modification.
The genes involved in GlcN modification are positively regulated
by the regulatory two-component system of protein virulence fac-
tors BvgAS (47, 48). In order to determine that there was no dif-
ference in the virulence status of these B. pertussis isolates, the
expression of ACT (adenylate cyclase toxin), a late gene regulated
by BvgAS, was determined by investigating the hemolysis capacity
of the bacterial isolates. Results showed that all strains tested in-
duced hemolysis, except for the Bvg strain used as negative con-
trol (see Fig. S5 in the supplemental material), indicating that the
lack of GlcN modification is not due to suppression of the BvgAS
two-component system.
Dendritic cell maturation by B. pertussis clinical isolates. To
verify the absence of TLR4 signaling by the B0442, B1120, and
B1121 B. pertussis isolates on a physiologically innate immune cell
type, human DCs, were used, and their effects on DC maturation
were compared to that induced by the Tohama I strain. The results
indicated that, compared to the medium control, the Tohama I
strain induced increased expression of all measured maturation
markers on MDDC, while the B0442 isolate induced increased
expression of CD40 and CD83 but not of CD80 or CD86 (Fig. 4).
Notably, the expression levels of CD40 and CD83 were signifi-
cantly lower than the levels induced by the Tohama I strain. After
incubation with the B1120 isolate, the expression of all markers
was significantly increased on the MDDC, yet the level of CD40
expression was significantly lower than that induced by incuba-
tion with Tohama I cells (Fig. 4). When the MDDC were incu-
bated with B1121, only the expression of CD83 was significantly
increased.Notably, the expression ofCD83was significantly lower
than that induced by the Tohama I strain. These results indicated
that isolates B0442 andB1121, and to a lesser extent B1120, are less
capable than Tohama I in activatingMDDC, based on the expres-
sion of surface markers.
In addition to the expression of surface maturation mark-
ers, MDDC secrete cytokines uponmaturation, which can steer
the adaptive immune response (2–5). Therefore, the levels of
cytokines secreted by the MDDC after incubation with live
bacteria were also determined. The Tohama I strain induced
the production of high levels of IL-10, IL-12p70, IL-23, IL-6,
and IL-8 by MDDC (Fig. 5). Isolates B0442 and B1121 induced
only low levels of IL-6, IL-8, and IL-10, and B1120 induced low
levels of IL-6, IL-8, IL-10, and IL-23 (Fig. 5). Notably, all cyto-
kine levels induced by these three strains were significantly
lower than the levels induced by the Tohama I strain. No dif-
ferences were observed in the levels of TNF- and IL-1 when
MDDC were incubated with the different isolates, and the lev-
els of TGF- could not be determined since they were under
the detection limit (data not shown). The expression of surface
maturation markers correlated with cytokine production by
MDDC, since isolates B0442 and B1121 induced no or low
expression of maturation markers and no IL-12p70 or low pro-
duction of IL-10, IL-6, and IL-8. The B1120 isolate did induce
modest expression of maturation markers, and although it did
not induce IL-12p70 and induced only low levels of IL-10, IL-6,
and IL-8, it did induce measurable levels of IL-23. The findings
here cannot be explained by toxic effects of these B. pertussis
strains on the MDDC, since no major differences were found in
DC viability according to FACS analysis (data not shown). To-
gether, these results indicated that the B. pertussis isolates B0442,
B1120, and B1121 fail to fullymatureDCs compared to Tohama I,
and this is most likely due to the differences in the LOS structures.
DISCUSSION
In this study, the capacities of different B. pertussis clinical isolates
to activate the innate immune system were assessed. Nineteen B.
pertussis isolates, representing major B. pertussis lineages, were
compared for their abilities to induce TLR2 and TLR4 signaling
(21). The B. pertussis isolates taken from pertussis patients in-
cluded currently emerging vaccine antigen-deficient strains as
well as the laboratory-adapted Tohama I strain and the B1121/18-
323 strain commonly used in experimental models to evaluate
whole-cell pertussis vaccines (28). We found, using human NF-
B/SEAP reporter HEK293 cell lines expressing human TLR4/
MD-2/CD14, that isolates B0442 and B1120, similar to the already
documented B1121/18-323 strain (44), did not induce TLR4 sig-
naling. Moreover, we could establish that the low activation of a
monocytic cell line by these three strains wasmainly TLR2 depen-
dent, whereas the stronger activation induced by the other strains
involved bothTLR2 andTLR4 signaling. Furthermore, these three
strains were poor inducers of in vitro DCmaturation. The lack of
TLR4 signaling is most likely due to the observed structural alter-
ation in the lipid A moieties of the LOS molecules derived from
these three strains. Interestingly, these strains could inhibit the
activation of HEK-TLR4 cells induced by E. coli LPS, suggesting
that the altered LOS structures act as TLR4 antagonists. These
results indicated that naturally occurring B. pertussis strains with
these alterations can infect humans and could have an effect on
activating innate immune cells, which in turn could affect pertus-
sis immunity in several ways.
First, reduced TLR4 signaling by B. pertussis can affect the
clearance of B. pertussis following infection, as indicated by in vivo
studies inwhich TLR4-deficientmice have been shown to bemore
sensitive to B. pertussis infection (6, 49). The crucial role of TLR4
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signaling for bacterial clearance is further supported by a study in
which the TLR4 ligand LOS was coadministered intranasally with
B. pertussis and no colonization of the bacterium in the lungs was
observed (50). This early protection against B. pertussiswas found
to be orchestrated byTLR4-dependent recruitment of neutrophils
(51). Our results showed that the B0442, B1120, and B1121 iso-
lates do not signal through TLR4 and induce less IL-8 production
by DCs than the Tohama I strain. This cytokine is important as a
chemoattractant and activator of neutrophils (52). Therefore, in-
duction of lower IL-8 production by these strains could lead to less
FIG 4 MDDCmaturation induced by live Tohama I, B0442, B1120, and B1121 B. pertussis isolates. (A and B) MDDC, cultured from monocytes isolated from
blood of healthy volunteers, were incubated for 48 h with the live B. pertussis isolates (OD, 4  104). The cells were stained for the costimulatory molecules
CD40, CD80, CD83, and CD86. (A) Representative histograms of CD40, CD80, CD83, and CD86 expression with the corresponding mean fluorescence
intensities (MFI). (B) MFI results relative to the MFI obtained after stimulation with the Tohama I strain (set at 100),  the standard deviation of at least 4
independent experiments with distinct donors. *, P	 0.05; **, P	 0.01; ***, P	 0.001; ****, P	 0.0001 versus medium control., P	 0.05;, P	 0.01;
, P	 0.001;, P	 0.0001 versus Tohama I.
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neutrophil recruitment and activation, which might result in de-
layed clearing of the bacterium.
Second, reduced TLR4 signaling byB. pertussis can affect adap-
tive immunity, which is essential for complete elimination of this
pathogen. Our results showed that the isolates that lacked TLR4
signaling induced less DCmaturation than the Tohama I strain, as
indicated by decreased expression of maturation markers as well
as cytokine production. Cytokines produced by DCs are essential
in steering the Th cell response, e.g., IL-12p70 for a Th1 response
(2, 3) and IL-1, IL-6, and IL-23 for a Th17 response (4, 5). In-
duction of a Th1 and Th17 response is important in the protective
immunity against B. pertussis infection (53–55). Indeed, after in-
cubation of DCs with the Tohama I strain, IL-12p70, IL-6, and
IL-23 secretion was induced, indicating that a Th1/Th17 type of T
cell response could be induced by these DCs, as previously shown
by others (8). Isolates B0442, B1120, and B1121 induced no pro-
duction of IL-12p70 and low production of IL-6 and IL-23 by
MDDC, which suggested that these isolates are less capable of
inducing a Th1/Th17 type of T cell response. DCs with immature
characteristics have been described to exhibit tolerogenic proper-
ties (56, 57). These tolerogenic DCs can induce the expansion of
regulatory T cells either by producing large amounts of IL-10 (56,
58, 59) or TGF- (60). It could be that strains B0442, B1120, and
B1121 induce tolerogenic DCs, resulting in the expansion of reg-
ulatory T cells as a strategy to suppress the adaptive immune re-
sponse against them. These strains, however, do not activate DCs
to produce high levels of IL-10, and the levels of TGF- were not
measurable, which could have been due to limitations of the assay.
To investigate whether these strains indeed induce tolerogenic
DCs that polarize T cells to a regulatory phenotype, cytokine pro-
filing of CD4 T cells cocultured with these DCs is required.
Third, pertussis-specific memory responses, induced by natu-
ral infection as well as by vaccination, might be suboptimally ac-
tivated by strains that fail to fully induce DC maturation. Indeed,
FIG 5 MDDC cytokine production induced by live Tohama I, B0442, B1120, and B1121 B. pertussis isolates. MDDC were incubated for 48 h with the live B.
pertussis isolates, after which the levels of IL-6, IL-8, IL-10, IL12p70, and IL-23 were measured in supernatants by using Luminex. Results shown are the mean
cytokine levels relative to the cytokine levels induced by the Tohama I strain (set at 100) the standard deviations from at least 5 independent experiments with
distinct donors. *, P	 0.05; **, P	 0.01; ***, P	 0.001; ****, P	 0.0001 versus medium control., P	 0.05;, P	 0.01;, P	 0.001;, P	
0.0001 versus Tohama I.
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several studies have shown that DCs not fully matured can inhibit
both aspecific and antigen-specific T cell activation (61, 62).
Therefore, B. pertussis strains that do not activate TLR4 could
affect immunity against this pathogen.
Marr et al. previously showed that the LOS of the commonly
used laboratory strain B1121/18-323 has a modified lipid A moi-
ety, namely, C10-OH or C12-OH acyl chains instead of C14-OH at
the C-3= position and lack of GlcNmodification (44). Using mass
spectrometry, we showed that this lipid A alteration described for
the B1121/18-323 strain also occurs in the clinical B. pertussis iso-
lates B1120 and B0442. Furthermore, a mutation in the lpxLA
gene, leading to an S173
L substitution, as also described recently
for B. pertussis 18-323 by Shah et al. (31), was observed in these
two strains. This substitution likely explains the presence of
C10-OH or C12-OH acyl chains instead of C14-OH at the C-3=
position of the lipid A molecule. Besides the alteration in the
length of the acyl chain on the C-3= position, a lack of GlcNmod-
ificationwas also foundwith all three isolates. Surprisingly, for the
isolates B0442 and B1120, no mutations were found in the genes
involved in GlcN modification, unlike a deletion mutation in the
lgmB gene described for the B1121/18-323 strain (31). In the Bvg
or virulent phase of the bacterium, the genes involved in the GlcN
modifications are transcribed, leading to the addition of GlcN to
the lipid A moieties (63). Notably, all isolates used in this study
induce hemolysis, which is mediated by ACT, a late Bvg-regulated
gene (63), indicating that the isolates are in the Bvgphase. There-
fore, the lack of GlcNmodifications is most likely not because the
bacteria are in the Bvg phase, and identification of the genes and
mechanisms involved here needs to be further investigated.
Alterations of LPS moieties by Gram-negative bacteria result-
ing in poor recognition by TLR4 have been described (64) and,
interestingly, the type of lipid A alteration can impact the viru-
lence of bacteria. Patients infected with Neisseria meningitidis
strainswith an lpxL1mutation, which leads to penta-acylated LPS,
had milder symptoms than patients infected with N. meningitidis
strains with wild-type hexa-acylated LPS (65). This lower viru-
lence of the lpxL1 mutant strains might be caused by two mecha-
nisms: decreased TLR4 activation or increased susceptibility to
other non-TLR4-dependent host defense mechanisms, such as
antimicrobial peptides (66). The naturally occurring B. pertussis
strains described here could also be less virulent due to similar
mechanisms. These strains do not activate TLR4 signaling and, in
addition, the lack of GlcN modification of the LOS molecules
leads to decreased resistance to antimicrobial peptides, as shown
in recent studies using GLcN mutants of B. pertussis and the
closely related B. bronchiseptica (67, 68). This however remains to
be investigated in larger clinical cohorts.
The identified clinical B. pertussis isolates, B0442, B1120, and
B1121, which lack the ability to induce TLR4 signaling, were all
found to be members of a lineage characterized by the ptxP4 per-
tussis toxin promoter allele. Whether there is an association be-
tween LPS alterations and the ptxP4 family still remains to be
investigated. Additional studies screening for larger numbers ofB.
pertussis strains isolated frompertussis patients are underway. It is
possible, though, that individuals infected with B. pertussis strains
with altered lipid A structures havemilder or no symptoms due to
decreased virulence of the bacteria, and they do not consult a
practitioner, which would result in an underestimation of the cir-
culation frequency of these strains. Strain analysis in active sur-
veillance programs in healthy individuals would be required to
address this issue.
Taken together, we found that B. pertussis isolates that fail to
induce TLR4 signaling due to alterations in their lipid Amolecules
occur naturally. This phenotype leads to reduced maturation of
DCs, and as a consequence, these strains may fail to induce a
protective immune response ormight suboptimally activate exist-
ing pertussis memory T cells, which were induced by vaccination
or natural infection. The alteration in the lipid A molecules may
therefore give the bacterium an advantage in evading the host
immune system and therefore establishing infection. Knowledge
regarding the strategies used by this pathogen on evading the host
immune response is, therefore, essential for the improvement of
current vaccines or for the development of new ones.
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